- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00460148
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- GSK Investigational Site
-
-
-
-
Eastern Cape
-
George, Eastern Cape, South Africa, 6529
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged between 30 and 85 years of age
- Body mass index of 18 to 32 kg/m2, body weight of at least 50 kg.
- Diagnosis of idiopathic Parkinson's disease
- Patients must have provided written informed consent prior to performing any study procedures
- QTc interval of < 450ms (or QTc < 480ms in patients with Bundle Branch Block).
Exclusion Criteria:
- Patients who have an abnormality on physical examination.
- Patients who have medical conditions which could present a safety concern.
- Patients who have a clinically significant abnormal laboratory value, ECG, or physical examination finding
- Positive result for Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV) antibody
- Positive alcohol test result and / or urine test for undeclared drugs
- Recent history of moderate to severe dizziness, syncope, or orthostatic hypotension
- Significant sleep disorder or Epworth Sleep Score (Appendix 5) > 9
- Patients with a lying/sitting diastolic blood pressure =110mmHg or =50mmHg or a systolic blood pressure =180mmHg or =90mmHg
- History of any dopaminergic treatment (other than ropinirole IR and L-dopa) within 2 weeks prior to first dose.
- Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 or induce CYP1A2
- Patients who smoke >20 cigarettes per day and will not maintain a constant smoking habit for the duration of the study.
- Blood donation or significant blood loss less than 90 days before Day 1 of the current study.
- Definite or suspected personal history, or family history, of adverse reactions or hypersensitivity to ropinirole or to drugs with a similar chemical structure.
- Use of any investigational drug (with the exception of ropinirole PR/CR) within 30 days or 5 half lives (whichever is longer) before the start of dosing with study medication.
- Patients who have received over-the-counter (OTC) medicine within 48 h before the first dose of study drug.
- Recent history, or suspicion, of drug dependence or abuse of alcohol
- Significant concern, or likelihood, that the patient will drop out of the study prematurely, will require new or prohibited concomitant medications during the study period, or will not be compliant with study procedures.
- Women who are pregnant or breast-feeding.
Female patient is currently either of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation).
(For purposes of this study, postmenopausal is defined as one year without menses) OR
child-bearing potential, has a negative urine/serum pregnancy test at the Screening Visit (prior to investigational product administration), and agrees to use acceptable contraception from one month prior to study Day 1 until one month after completion of the study (ie. one month after the follow-up visit). All hormonal birth control must have been administered for at least one monthly cycle prior to the Screening Visit. GSK acceptable contraception methods, when used consistently and in accordance with both the product label and the instructions of a physician, are as follows:
- complete abstinence
- sterilization of patient's male partner prior to female patient's entry into study
- oral contraceptive (either combined or progestogen only)
- any intra-uterine device with a documented failure rate of less than 1% per year
- systemic contraception (eg. norplant system)
- double barrier method if comprised of a spermicide with either a condom or diaphragm
- Patients with prior or current major psychosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ropinirole AUC, the area under the plasma concentration-time curve over 24 hours Ropinirole maximum plasma concentration over 24 hours
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to attain the maximum plasma concentration Incidence of adverse events over 37 days As above, but for ropinirole metabolites
Time Frame: over 37 days
|
over 37 days
|
Vital signs, ECG and clinical laboratory data over 37 days
Time Frame: over 37 days
|
over 37 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- This study has not been published in the scientific literature.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Ropinirole
Other Study ID Numbers
- ROP109087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: ROP109087Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Ropinirole
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompletedParkinson DiseaseSpain, France, Bulgaria, United Kingdom, Germany, Hungary, Russian Federation, South Africa, Italy, Canada, Czechia, Poland, Romania, Ukraine
-
Titan PharmaceuticalsTerminatedParkinson DiseaseUnited States
-
St. Luke's-Roosevelt Hospital CenterGlaxoSmithKlineCompletedSexual DysfunctionUnited States
-
GlaxoSmithKlineCompletedRestless Legs SyndromeJapan
-
Lupin Ltd.CompletedPharmacokinetic StudyIndia